Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
AutoSurvey2: Empowering Researchers with Next Level Automated Literature Surveys
arXiv:2510.26012v3 Announce Type: replace Abstract: The rapid growth of research literature, particularly in large language models (LLMs), has made producing comprehensive and current survey papers increasingly difficult. This paper introduces autosurvey2, a multi-stage pipeline that automates survey generation through retrieval-augmented synthesis and structured evaluation. The system integrates parallel section generation, iterative refinement, and real-time retrieval of recent publications t
-
cs.AI, q-bio.NC updates on arXiv.org
-
Synthetic Clinical Notes for Rare ICD Codes: A Data-Centric Framework for Long-Tail Medical Coding
arXiv:2511.14112v1 Announce Type: cross Abstract: Automatic ICD coding from clinical text is a critical task in medical NLP but remains hindered by the extreme long-tail distribution of diagnostic codes. Thousands of rare and zero-shot ICD codes are severely underrepresented in datasets like MIMIC-III, leading to low macro-F1 scores. In this work, we propose a data-centric framework that generates high-quality synthetic discharge summaries to mitigate this imbalance. Our method constructs reali
Synthetic Clinical Notes for Rare ICD Codes: A Data-Centric Framework for Long-Tail Medical Coding
-
Cell Death Discovery nature.com science feeds
-
Protein lipoylation in cancer: metabolic reprogramming and therapeutic potential
Cell Death Discovery, Published online: 02 September 2025; doi:10.1038/s41420-025-02718-zProtein lipoylation in cancer: metabolic reprogramming and therapeutic potential
Protein lipoylation in cancer: metabolic reprogramming and therapeutic potential
Cell Death Discovery, Published online: 02 September 2025; doi:10.1038/s41420-025-02718-z
Protein lipoylation in cancer: metabolic reprogramming and therapeutic potential-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Advances in molecular pathology and therapy of non-small cell lung cancer
Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.ABSTRACTOver the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifying the breadth and depth of the therapeutic effect requires comprehending and integrating diverse and profound progre
Advances in molecular pathology and therapy of non-small cell lung cancer
Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6.
ABSTRACT
Over the past two decades, non-small cell lung cancer (NSCLC) has witnessed encouraging advancements in basic and clinical research. However, substantial unmet needs remain for patients worldwide, as drug resistance persists as an inevitable reality. Meanwhile, the journey towards amplifying the breadth and depth of the therapeutic effect requires comprehending and integrating diverse and profound progress. In this review, therefore, we aim to comprehensively present such progress that spans the various aspects of molecular pathology, encompassing elucidations of metastatic mechanisms, identification of therapeutic targets, and dissection of spatial omics. Additionally, we also highlight the numerous small molecule and antibody drugs, encompassing their application alone or in combination, across later-line, frontline, neoadjuvant or adjuvant settings. Then, we elaborate on drug resistance mechanisms, mainly involving targeted therapies and immunotherapies, revealed by our proposed theoretical models to clarify interactions between cancer cells and a variety of non-malignant cells, as well as almost all the biological regulatory pathways. Finally, we outline mechanistic perspectives to pursue innovative treatments of NSCLC, through leveraging artificial intelligence to incorporate the latest insights into the design of finely-tuned, biomarker-driven combination strategies. This review not only provides an overview of the various strategies of how to reshape available armamentarium, but also illustrates an example of clinical translation of how to develop novel targeted drugs, to revolutionize therapeutic landscape for NSCLC.
PMID:40517166 | PMC:PMC12167388 | DOI:10.1038/s41392-025-02243-6